- Home
- CISO vs KPRX Comparison
CISO vs KPRX Comparison
Compare CISO & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- KPRX
- Stock Information
- Founded
- CISO 2015
- KPRX 1998
- Country
- CISO United States
- KPRX United States
- Employees
- CISO N/A
- KPRX N/A
- Industry
- CISO Computer Software: Prepackaged Software
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CISO Technology
- KPRX Health Care
- Exchange
- CISO Nasdaq
- KPRX Nasdaq
- Market Cap
- CISO 10.5M
- KPRX 11.0M
- IPO Year
- CISO N/A
- KPRX N/A
- Fundamental
- Price
- CISO $1.09
- KPRX $3.29
- Analyst Decision
- CISO
- KPRX Strong Buy
- Analyst Count
- CISO 0
- KPRX 1
- Target Price
- CISO N/A
- KPRX $10.00
- AVG Volume (30 Days)
- CISO 43.7K
- KPRX 46.7K
- Earning Date
- CISO 11-26-2024
- KPRX 11-26-2024
- Dividend Yield
- CISO N/A
- KPRX N/A
- EPS Growth
- CISO N/A
- KPRX N/A
- EPS
- CISO N/A
- KPRX 1.53
- Revenue
- CISO $55,807,138.00
- KPRX $16,020,000.00
- Revenue This Year
- CISO $78.76
- KPRX N/A
- Revenue Next Year
- CISO N/A
- KPRX N/A
- P/E Ratio
- CISO N/A
- KPRX $2.10
- Revenue Growth
- CISO 29.55
- KPRX N/A
- 52 Week Low
- CISO $0.26
- KPRX $3.00
- 52 Week High
- CISO $3.60
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- CISO 72.53
- KPRX 41.12
- Support Level
- CISO $0.73
- KPRX $3.47
- Resistance Level
- CISO $0.92
- KPRX $3.75
- Average True Range (ATR)
- CISO 0.09
- KPRX 0.23
- MACD
- CISO 0.01
- KPRX -0.03
- Stochastic Oscillator
- CISO 100.00
- KPRX 15.06
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.